John...After the FDA approved Vascepa for the CVD indication, J.T. was not interested in selling Amarin...This was based on JT's expectations that Vascepa would become a blockbuster drug, globally...Post the Judge Du debacle, selling came more into focus....After J.T.'s departure, and with Amarin now in the hands of new management, selling the company became an even better strategy...since Amarin now realized that it would lack sufficient assets to achieve it's original goal of worldwide sales.